

# Index

Note: page numbers in *italics* refer to figures and tables

- acetylcholine 191, 192
- acne 30
- activation function 1 (AF-1) 40, 41
- activator protein 1 (AP-1) 57
  - activation suppression by LABA 176
  - cross-talk with GR 115–16
  - GR binding 10, 110
  - induction by MIF 147
  - nucleosome effects 129
  - regulation by p38 MAPK pathway 129
- adalimumab 199
- adenosine triphosphate (ATP) 207
- adrenal function monitoring 24
- adrenal insufficiency 23–4
- adrenocorticotrophic hormone (ACTH) 23–4
  - GC insensitivity 73
  - GC resistance 73, 75
- aerosol(s)
  - formulation 264
  - propellants 262, 270
- aerosol delivery 262
  - breathing components 266
  - service 264
- aerosol deposition
  - assessment 266–9
  - enhancement 265
  - factors affecting 264–6
  - mechanisms 263–4
  - pharmacokinetic methods 267–8
  - predictive models 266–7
  - in respiratory tract 263–6
  - in vitro* methods 267
- aerosol generation devices 269–74
- airflow obstruction, persistent 98
- airway
  - calibre 266
  - eosinophilic inflammation 90, 99
  - inhaled corticosteroids with LABA 171–2
  - remodelling 172
  - responsiveness in corticosteroid-resistant asthma 99
  - wall remodelling reversal 90
- allergy, glucocorticoids 29
- ALOX5 gene 193–4
- ALOX15 gene 245
- alveolar macrophages
  - glucocorticoid sensitivity 9–10
  - severe asthma 100
  - steroid insensitivity 212
- amino-terminal transactivation domain (NTD) 40, 41, 43
- androstenedione 73
- antibiotics, steroid-sparing strategy 197–8
- anticholinergics, steroid-sparing therapy 191–2
- antidepressants 64
- anti-IgE therapy, steroid-sparing strategy 196–7
- anti-inflammatory mediators 191
- anti-inflammatory therapy 65
- anti-MIF MAb 150
- antioxidants
  - asthma 120
  - COPD 65
- apoptosis
  - JNK 222
  - myocytes 27
  - neutrophil 219
  - regulation by NF- $\kappa$ B 213
- arachidonate 5-lipoxygenase (ALOX5)
  - gene 193–4
- arachidonate 15-lipoxygenase (ALOX15)
  - gene 245
- AS-605240 227, 228
- aspartate aminotransferase (AAT) 28
- asthma 1, 2, 55–6
  - airway calibre 266
  - airway eosinophilic inflammation 90, 99
  - airway lymphocytic inflammation 90
  - airway remodelling 172

- asthma (*Continued*)
- ALOX5 inhibitors 193
  - antioxidants 120
  - $\beta_2$ -agonist therapy 191
  - Chlamydia pneumoniae* infection 197
  - control maintenance 166–7
  - corticosteroid inhibitory effects 115–16
  - corticosteroid insensitivity 90–1, 92, 109, 111
  - corticosteroid responsiveness 89–103, 109
  - corticosteroid-dependent 99
  - corticosteroid-resistant 90–1
  - CysLTs 195–6
  - Cytokines 99–100, 245
  - difficult-to-control 97, 98
  - epigenetics 119–20
  - exacerbations 165–6
  - FEV<sub>1</sub> 93–4, 95–6
  - fluticasone propionate absorption 254
  - GC-dependent 200
  - GC-insensitive 110–11, 112, 113–120
  - GCs 20–1, 57–8
  - HDAC activity reduction 120, 176
  - inflammatory cascade 56–7
  - inhaled corticosteroid therapy 20–1, 89–90, 163–78
  - LABA steroid-sparing 163–78
  - leukotriene B<sub>4</sub> 195
  - leukotriene receptor antagonists 195–6
  - leukotriene synthesis inhibitors 195–6
  - membrane receptors 12
  - MIF overexpression 147–8
  - NF- $\kappa$ B in inflammatory response 116, 118, 119
  - nocturnal 99–100
  - omalizumab 197
  - oxidative stress 138
  - pathogenesis 56
  - PDE4 inhibitors 190
  - peak expiratory flow 92–3
  - prednisolone response 93–4
  - severe 97–101
  - SMART concept 168–70
  - steroid-sparing 163–78, 186–7
  - theophylline 186–7
  - TNF- $\alpha$  inhibitors 199–200
- atherosclerotic vascular disease 148
- $\beta_2$ -agonists
- asthma treatment 191
  - inhaled short-acting 192
  - see also* long-acting inhaled  $\beta_2$ -agonists (LABA)
- BAY 61-3606 229, 230
- beclomethasone dipropionate 164
- tissue metabolism 252
  - transporter induction 251
- BIRB796 221
- blood–brain barrier 251
- BMS-354451 211, 214
- bone, GC effects 25–6
- bone density
- Cushing's syndrome 25
  - monitoring 26
- bone morphogenetic proteins 2 (BMP-2) 26
- breathing manoeuvre
- components 266
  - dry powder inhalers 271–2
- Brg1 chromatin remodelling protein 4, 9–10
- bronchial hyper-responsiveness
- asthma 90
  - corticosteroid responsiveness 100
- bronchioles, inflammation 56
- bronchoconstriction 266
- bronchodilators, COPD 191–2
- Brownian motion 263
- budesonide 163–4, 165
- aerosol deposition assessment 268
  - airway remodelling 172
  - dose/timing with inhaled corticosteroids 174
  - dosing frequency 177
  - esterification 254–5
  - inflammatory cells 173
  - Symbicort® 168–70, 171
- calcium absorption 26
- candidiasis, oesophageal/oral 22
- cascade impactors 267
- cataract, GC-induced 31, 32
- CC-401 223
- CD8<sup>+</sup> T cells 56
- c-fos 115
- chaperone acetyltransferase (CHAT) 10
- charcoal block 268
- chemokines 191
- children
- growth retardation 24–5
  - inhaled glucocorticoids for asthma 20–1
- Chlamydia pneumoniae* 197, 198
- chlorofluorocarbons (CFCs) 262, 270
- chromatin 1–2
- acetylation 140
- chronic obstructive pulmonary disease (COPD) 1, 2, 55–6
- alveolar macrophages 9
  - bronchodilators 191–2
  - Chlamydia pneumoniae* infection 198
  - Corticosteroids 65, 101–2
  - FEV<sub>1</sub> 101
  - HDACs 137–8, 186
  - histone acetylation 135
  - 4-HNE in pathogenesis 137, 138
  - 5-lipoxygenase inhibitors 196

- MIF 148
- NF- $\kappa$ B inflammatory gene regulation 127–8
- oxidative stress 65, 138, 186
- p38 inhibitors 219
- p65 expression 208
- pathogenesis 56
- PDE4 inhibitors 190
- reactive oxygen species 65
- theophylline as steroid-sparing strategy 186–8
- TNF- $\alpha$  inhibitors 199, 200
- ciclesonide 249, 252
- cigarette smoke/smokers
  - corticosteroids 101–2, 134–7
  - HDAC inhibitory effects 119–20
  - HDAC2 138
  - histone acetylation 135, 212
  - NF- $\kappa$ B pro-inflammatory gene expression 127–9
  - oxidative stress 125, 126–7, 135–6
- cilomilast 189, 190, 191
- c-jun 115–16
- c-jun N-terminal kinase *see* JNK
- clarithromycin 197–8
- coactivators 64, 136
  - recruitment 131
- collagens 30
- contact dermatitis 29
- corepressor complex 136
- corepressors 64
- corticosteroid(s) 129–31, 132, 133
  - activity rank order 244–5
  - adjustable dosing regimen 167–8
  - adverse effects 244
  - anti-inflammatory effect mediation through GRs 110
  - anti-inflammatory gene transcription induction 118
  - asthma 20–1, 89–90, 163–78
  - asthma inhibitory effects 115–16
  - asthma responsiveness 89–103, 109
  - circadian factors 255
  - COPD 101–2
  - dependency in Crohn's disease/ulcerative colitis 102
  - dissolved 242–3
  - dose reduction 167–70
  - dose/timing with LABA 174–5
  - dosing frequency with LABA 177–8
  - drug transporters 250–2
  - esterification 254–5
  - hepatic metabolism 246, 248, 252
  - high-dose in severe asthma 98
  - inflammation suppression mechanism 134–5
  - inflammatory mediator release suppression 131
  - inhaled therapy 89–90, 94–7, 166–78, 249, 250, 252
  - LABA 164–78
  - NF- $\kappa$ B expression suppression 131
  - non-genomic effects 131
  - oral 91–4, 243, 252–3
  - pharmacodynamics 241–3, 244–5
  - pharmacokinetics 241–3, 245–55
  - pulmonary deposition 253–4
  - pulmonary efficacy/safety 241–3
  - pulmonary fate 247–8
  - pulmonary selectivity modulation 242
  - resistance 102, 134–7
  - responses in PBMCs 112–13
  - responsiveness, cigarette smokers/COPD 101–2
  - responsiveness, normal population 96
  - sensitivity 91, 241–55
  - signalling pathway 112
  - systemic absorption 243
  - systemic in severe asthma 100–1
  - therapeutic response 90–1
  - transactivation of gene expression 130–1, 244
  - transrepression of gene expression 131, 132, 244
- corticosteroid insensitivity
  - asthma 92, 109, 111
  - defective histone acetylation 118
  - definition 90–1
  - GR $\beta$  111, 245
  - HDAC 119–20
  - signalling through MAPK 114
  - syndromes 102
  - systemic clearance 247–8
  - see also* glucocorticoid (GC) insensitivity
- corticosteroid-resistant asthma 90–1
- corticosterone 73
- corticotrophin-releasing hormone (CRH) 23
- corticotrophin-releasing hormone (CRH) receptor
  - gene polymorphism 97
- cortisol
  - GC insensitivity 73
  - GC resistance 73, 75
  - plasma concentrations 255
- cough, inhaled GCs 22
- Crohn's disease, steroid dependency 102
- curcumin 140
- Cushing's syndrome
  - bone density 25
  - diabetes mellitus 28
  - GC insensitivity 75
  - iatrogenic 22–3
- cyclo-oxygenase 2 (COX-2) 147
  - MIF induction 150
- CYP3A 252–3

- CYP3A4 inhibitors 248, 253  
cysteinyl leukotrienes (CysLTs) 193, 194, 195–6  
cytokines  
  expression in asthma 245  
  GC affinity reduction for GRs 245  
  LPS-induced 211  
  multiple 191  
  release by PBMCs 99–100  
cytoplasmic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>) 147
- Datura* 261–2  
dehydroepiandrosterone (DHEA) 73  
deoxycorticosterone (DOC) 73  
dermatitis  
  contact 29  
  perioral hirsutism 30  
dexamethasone  
  binding studies 83  
  structural modifications 63  
  suppression 73  
DHEA sulphate (DHEAS) 73  
diabetes mellitus  
  Cushing's syndrome 28  
  mechanisms 60  
  organ transplantation 28  
diffusional transport 263, 264  
1,25-dihydroxyvitamin D 26  
DNA binding 41, 42  
DNA binding domain LBD 40, 41  
drug transporters 250–2  
dry powder inhalers (DPIs) 262, 266, 270, 271–2  
dysphonia, inhaled GCs 22
- e-flow nebulizer 273  
eosinophilic inflammation of airway  
  asthma 90  
  corticosteroid-dependent asthma 99  
epidermal growth factor receptor (EGFR) 206, 207  
epidermal growth factor receptor (EGFR)  
  antagonists 227  
etanercept 199  
ETS transcription factors, GR binding 62, 64  
extracellular matrix (ECM) proteins 30  
extracellular signal-regulated kinase (ERK)  
  113–14, 149, 215  
eye, GC effects 31–2
- familial GC resistance syndrome 110  
fibroblast proliferation 30  
fibroblast-like synoviocytes (FLS) 146, 147, 150  
  MIF regulation by GC 151  
fluticasone propionate 163–5  
  aerosol deposition assessment 268  
  airway remodelling 172  
  dose/timing with inhaled corticosteroids 174  
  GR translocation 175  
  inflammatory cells 173  
  mucociliary clearance 254  
  forced expiratory volume in 1 second (FEV<sub>1</sub>)  
  asthma 93–4, 95–6  
  COPD 101  
  time–response profile curves 265  
formoterol 163, 164, 165–6  
  airway remodelling 172  
  dose/timing with inhaled corticosteroids 174  
  GR translocation 175–6  
  inflammatory cells 173  
  Symbicort® 168–70, 171  
fractures 26, 27
- gastrointestinal tract transporters 251  
genes  
  transactivation 3–5, 59, 60, 130–1, 177, 244  
  transcription 176–7  
  translocation 175–6  
  transrepression 59, 60, 131, 132, 176–7, 244  
glaucoma, GC-induced 31–2  
glucocorticoid(s) (GCs)  
  activity rank order 244–5  
  allergy 29  
  anti-inflammatory effects 6  
  bone loss 25, 26  
  cellular responsiveness 39–40  
  cellular sensitivity regulation 45  
  circadian factors 255  
  clearance 246–8  
  clinical responsiveness 64  
  compliance 246  
  dissociated 60–2  
  drug distribution 248–50  
  drug transporters 250–2  
  endogenous 55  
  esterification 254–5  
  eye effects 31  
  half-life 246  
  HDAC2 role 8–9  
  hepatic metabolism 246, 248, 252  
  inflammation effects 57–8  
  inflammatory gene suppression 212  
  inhaled 20–33, 57–8  
  local treatment 20–1  
  MAPK activity suppression 11  
  mechanisms of action 1–2, 58, 59, 60  
  membrane receptors 12  
  MIF 151–5  
  mRNA stability regulation 11–12  
  non-genomic actions 12  
  novel drug addition 64  
  oral administration 20, 22–33

- oral bioavailability 252–3
- pharmacodynamics 241–3, 244–5
- pharmacokinetics 241–3, 245–55
- plasma protein binding 249, 250
- protein binding 248–50
- pulmonary deposition 253–4
- pulmonary fate 247–8
- sensitivity 9–10, 151–5
- side effects 19–34, 55
- signal transduction 76, 83
- signalling and polyphenols 138, 139, 140–1
- skin effects 29–31
- splice variants 47
- tissue metabolism 252
- tissue responsiveness 40
- tissue-specific resistance 40
- transrepression pathway selectivity 60–1
  - see also* long-acting inhaled  $\beta_2$ -agonists (LABA)
- glucocorticoid (GC) insensitivity 64–5, 73–86
  - asthma 109–11, 112, 113–20
  - clinical manifestations 74
  - diagnostic evaluation 74
  - differential diagnosis 75
  - molecular defects 77, 78–9
  - molecular mechanisms 75–7, 78–9, 80, 81, 82–5
  - treatment 75
  - see also* corticosteroid insensitivity
- glucocorticoid receptor interacting protein 1 (GRIP-1) 76, 84, 85
- glucocorticoid receptors (GR) 2, 130
  - abnormalities 110–11, 112
  - acetylation 6, 9, 133
  - altered binding affinity 111
  - alternative splicing 43, 44, 45–7
  - alternative translation initiation 47–9
  - AP-1-induced gene transcription 10–11
  - binding to DNA 131
  - coactivator/corepressor complexes 4–5
  - corticosteroid anti-inflammatory mediation 110
  - cross-talk 62, 64, 115–6
  - deacetylation 6, 7, 9
  - dissolved corticosteroid interaction 242–3
  - DNA binding 41, 42
  - domains 40, 41, 43
  - function 40, 41, 42–3
  - gene induction 2–3
  - HDAC2 role 8–9
  - hsp90 acetylation 10, 110
  - interactions 130–1, 132
  - isoforms 40, 43, 44, 45, 245
  - ligand binding 5, 110
  - ligand binding domain 2, 81
  - molecular mechanisms 1–13
    - mutations 76, 77, 80–5
    - NF- $\kappa$ B cross-talk 7–8
    - nitrosylation 136
    - non-steroidal ligands 61
    - nuclear export 3
    - nuclear translocation 112–14, 118
    - phosphorylation 5–6, 114
    - post-translational modifications 5–6, 43
    - regulation 40
    - subtypes 39–50
    - sumoylation 43
    - transactivation 3–5, 59, 60
    - transcription factor activity modulation 41, 42–3
    - transcriptional coactivators 4
    - translocation 175–6
    - transrepression 59, 60
    - see also* human glucocorticoid receptor (hGR)
- glucocorticoid receptors–hsp90 complex 12
- glucocorticoid (GC) resistance 47
  - mechanisms 112
  - molecular defects 77, 78–9
  - molecular mechanisms 75–7, 78–9, 80, 81, 82–5
  - reversing 138, 139, 140–1
- glucocorticoid response elements (GREs) 3, 28
  - binding by GR $\beta$  130
  - GR binding 58, 110
  - negative 131
- glucocorticoid-sparing approaches to anti-inflammatory therapy 65
- glutamine 27
- glycogen storage 28
- GR $\alpha$  43, 44, 45, 47
  - glucocorticoid function 130
  - subtypes 48, 49
  - translational isoforms 48–9
- GR $\beta$  43, 44, 45–6
  - corticosteroid insensitivity 111, 245
  - function 130
- GR $\gamma$  47
- granulocyte–macrophage colony stimulating factor (GM-CSF) 171
  - alveolar macrophage release 212
- grapefruit juice, glucocorticoid availability 248
- gravitational sedimentation 263, 264
- GR–GR homodimers 131
- growth factors 191
- growth hormone (GH) expression regulation by GCs 25
- growth retardation 24–5
- helium, aerosol deposition enhancement 265
- histone acetylases 176, 212

- histone acetylation 1–2, 3–5, 6, 129, 212  
   cigarette smokers 135, 212  
   COPD 135  
   defects 116, 118  
 histone acetyltransferase (HAT) 116, 117, 118  
   activity regulation by corticosteroids 134–5  
   HDAC imbalance 140  
   non-histone protein acetylation 133  
 histone deacetylase (HDAC) 116, 117, 118, 119–20  
   activity regulation by corticosteroids 134–5  
   anti-inflammatory activity 131, 132  
   classes 133–4  
   COPD 137–8, 186  
   corticosteroid insensitivity 119–20  
   deacetylation promotion 6, 7, 212  
   HAT imbalance 140  
   inflammatory gene suppression 185–6  
   non-histone protein deacetylation 133  
   post-translational modifications 137–8  
   severe asthma 176  
   theophylline 120, 138  
 histone deacetylase 1 (HDAC1) 136–7  
 histone deacetylase 2 (HDAC2) 118, 119  
   cigarette smokers 138  
   COPD 186  
   corticosteroid resistance 135–6  
   GC suppression of inflammatory genes 212  
   glucocorticoid function 8–9  
   overexpression 9–10  
   PI3K inhibitors 226  
   selective inducers 140  
   steroid-mediated recruitment 140  
 histone deacetylase 3 (HDAC3) 137  
 histone deacetylation 129  
   promotion 6, 7, 212  
 hoarseness 22  
 hsp27 217–18  
 hsp90 41, 42, 110  
   acetylation 10  
   GR complex 12  
 human glucocorticoid receptor (hGR)  
   ligand binding domain crystal structure 81  
   point mutations 82–5  
 hydrofluorocarbons (HFCs) 270  
 hydrogen peroxide 125  
 4-hydroxy-2-nonenal (4-HNE) 137, 138  
 hydroxyl radical 125  
 hygroscopic growth 266  
 hypercortisolism 28  
 hyperglycaemia 27–8  
 hypogonadism, osteoporosis association 26  
 hypothalamic–pituitary–adrenal (HPA) axis  
   23–4, 26  
   dexamethasone suppression resistance 73  
   GC resistance 73, 74  
   psychiatric side effects 33  
 IC87114 225–6, 227, 228  
 IL-2-inducible kinase (ITK) 206, 230  
 immune activation 109  
 immune response  
   circadian rhythm 255  
   NF- $\kappa$ B 56–7  
 immunoglobulin E (IgE) high-affinity  
   receptors 196–7  
 I-neb system 273–4  
 inertial impaction 263, 264  
 infection, GC side effects 28–9  
 inflammation  
   GC effects 57–8  
   steroid-insensitive 211–13, 219, 226  
   tissue 109  
 inflammatory cascade, NF- $\kappa$ B 56–7  
 inflammatory cells, inhaled corticosteroids with  
   LABA 173–4  
 inflammatory disease, MIF 145–8  
 inflammatory gene expression 58, 59, 60  
 inflammatory gene transcription, p38 MAPK  
   signalling 218  
 inflammatory process, wound healing 30  
 inflammatory response, NF- $\kappa$ B 56–7  
 inflammatory signalling, kinases 206  
 inflammatory stimuli, external 205  
 infliximab 199  
 inhaled drug therapy  
   aerosol deposition 263–6  
   aerosol generation devices 269–74  
   history 261–2  
   *see also* corticosteroid(s), inhaled therapy;  
   glucocorticoid(s) (GCs), inhaled  
 inhaler devices, new 269–74  
 inhibitor of NF- $\kappa$ B kinase (IKK) 57, 206  
   activation 127–8, 210  
   MIF effect 153  
   small-molecule inhibitors 140, 210–11  
 inhibitor of NF- $\kappa$ B kinase 2 (IKK2) 56–7, 65  
 inhibitor of NF- $\kappa$ B kinase (IKK) inhibitors  
   210–11, 212, 213, 214–15  
 insulin resistance 27–8  
   mechanisms 60  
 insulin-like growth factor 1 (IGF-1) 26, 27  
 intercellular adhesion molecule 1 (ICAM-1) 172  
 interleukin 1 (IL-1) 150  
 interleukin 8 (IL-8) 171  
   alveolar macrophage release 212  
   corticosteroid-dependent asthma 99  
 intraocular pressure (IOP) 31–2  
 Irresa 227, 228  
 ITK inhibitors 230

- Janus kinase (JAK) 57  
 Janus kinase (JAK) inhibitors 227, 230  
 jet nebulizers 272, 273  
 JNK 113, 114, 115–16, 215  
   activation 222  
   isoforms 221, 222  
   MIF effect 155  
   signalling 222  
   stress-induced apoptosis 222  
   targeting 221–3  
 JNK inhibitors 222  
   small-molecule 223
- keratinocyte proliferation 30  
 ketoconazole, glucocorticoid availability 248  
 ketolides, steroid-sparing strategy 197–8  
 kinase inhibitors 206–7, 228–9  
 kinases 205–31  
   DFG out conformation 207, 221  
   families 206  
   inflammatory signalling 206  
   NF- $\kappa$ B activation targeting 208–13, 214–15  
   pharmacological targeting 206–8  
   small molecule inhibitors 205  
   targets 227, 230
- leukotriene(s) 193–4  
 leukotriene A<sub>4</sub> 193  
 leukotriene B<sub>4</sub> 194  
   asthma 195  
 leukotriene B<sub>4</sub> receptor antagonists 196  
 leukotriene C<sub>4</sub> 194  
 leukotriene receptor antagonists 193–6  
 leukotriene synthesis inhibitors 193–6  
 ligand-binding domain (LBD) 40, 41  
 lipid peroxidation products 127  
 lipopolysaccharide  
   cytokine induction 211  
   inflammatory stimulus 209–10  
 5-lipoxygenase inhibitors 196  
 liver, glycogen storage 28  
 liver X receptors (LXRs) 8, 64  
 long-acting inhaled  $\beta_2$ -agonists (LABA) 163–78  
   anti-leukotriene additive effect in asthma 195  
   inhaled corticosteroids 166–8, 170–78  
   lower dose effects 164–5  
   theophylline combination 188  
   tiotropium additive effect 192
- lungs  
   aerosol deposition 262–74  
   inflammation of parenchyma 56  
   inhaled corticosteroids with LABA 171–2  
   radionuclide imaging 268–9  
   transporters 251  
   ventilation imaged 269  
   lymphocytic inflammation of airway in  
     asthma 90  
 LYS294002 223, 228
- macrolides, steroid-sparing strategy 197–8  
 macrophage migration inhibitory factor  
   (MIF) 145–55  
   AP-1 induction 147  
   asthma 147–8  
   atherosclerotic vascular disease 148  
   COPD 148  
   GCs 151–2, 153, 154–5  
   indirect effects 150  
   inflammatory disease 145–8  
   JNK effect 155  
   MAP kinases 153–4, 155  
   mechanisms of action 149–51  
   p53 150, 154–5  
   pro-inflammatory factor 145–51  
   rheumatoid arthritis 146–9  
   systemic lupus erythematosus 148
- macrophages  
   COPD 56  
   steroid insensitivity 212
- mast cells, activated 99  
 MDR1 efflux transporter 250, 251  
 MEK inhibitor 215  
 metered dose inhaler *see* pressurized metered dose  
   inhaler (pMDI)  
 methylprednisolone, systemic 100  
 mitogen-activated protein kinase (MAPK) 57,  
   206  
   activity suppression 11  
   MIF 149–50, 153–4  
   targeting 215–23  
   *see also* p38 MAPK
- mitogen-activated protein kinase (MAPK)  
   inhibitors 214–15  
 mitogen-activated protein kinase phosphatase-1  
   (MKP-1) 176–7  
 MMTV promoter 82, 83, 85  
   induction 136  
 mometasone furoate 249, 254  
 montelukast 195, 196  
 mood disorders, GC-induced 32–3  
 mRNA  
   expression 30  
   GC effects 60  
   regulation by p38 MAPK 217  
   stability regulation 11–12  
 mucociliary transporter 254  
 multidrug resistance protein 1 (MRP1) 194  
 muscle, GC therapy effects 27

- Mycoplasma pneumoniae* 197  
myocytes, apoptosis 27  
myopathy, GC-induced 27  
myostatin 27
- nebulizers 270  
  breath-enhanced 272–3  
  breathing pattern control 274  
  conventional 272  
  new technologies 272–4  
  personalized smart-card technology 274  
  vibrating mesh technology 273–4
- nedocromil 268, 269
- neutrophils  
  apoptosis 219  
  COPD 56
- nitric oxide 120, 125  
  smoke-derived 137–8
- nitric oxide synthase (NOS) inhibitors 120
- nitrogen species, COPD 65
- nuclear factor  $\kappa$ B (NF- $\kappa$ B) 56–7  
  absence of MIF activation 149–50  
  activation 6–7, 57, 176, 208–10  
  activity repression 118, 119  
  anti-inflammatory gene transcription 118  
  apoptosis regulation 213  
  chromatin acetylation 140  
  expression suppression by corticosteroids 131  
  GR binding 110  
  GR cross-talk 7–8  
  inflammatory response in asthma 116, 118, 119  
  inhibition 153  
  kinases targeting activation 208–13, 214–15  
  nucleosome effects 129  
  p65 subunit 208  
  pro-inflammatory gene expression 127–9  
  regulation by p38 MAPK pathway 129  
  signalling pathway 208–9  
  skin homeostasis regulation 213  
  transcriptional effect inhibition 65
- nucleosome 129
- omalizumab 196–7
- open vent nebulizers 272–3
- organ transplantation, diabetes 28
- osteoblasts 26
- osteoclasts 26
- osteocytes 26
- osteoporosis 25–6
- osteoprotegerin (OPG) 26
- oxidants  
  inhaled 126–7  
  *see also* reactive oxygen species
- oxidative stress 125–7
- asthma 138  
cigarette smoke 125, 126–7, 135–6  
COPD 65, 138, 186, 211–12  
histone deacetylase inhibitory effects 119–20  
NF- $\kappa$ B pro-inflammatory gene  
  expression 127–9
- p38 inhibitors 218  
  anti-inflammatory effects 220–1  
  COPD 219  
  safety 221  
  small-molecule 219–21  
  steroid-insensitive inflammation 219  
  substrate-selective 221
- p38 MAPK 111, 113, 215  
  GR phosphorylation 137  
  inflammatory gene transcription 218  
  isozymes 216–17  
  mRNA regulation 217  
  neutrophil apoptosis inhibition 219  
  targeting 216–21  
  transcription factor regulation 129, 217
- p38 MAPK inhibitors 140–1  
  small-molecule 219–21
- p53 tumour suppressor protein 150  
  MIF effects 154–5
- p65, COPD 208
- parathyroid hormone (PTH) 26
- particle density 264
- particle size 264–6  
  distribution 267  
  hygroscopic growth 266
- peak expiratory flow rate (PEFR) 92–3
- peripheral blood mononuclear cells (PBMCs)  
  cytokine release in asthma 99–100  
  ligand binding studies 111  
  responses to CS 112–13
- peroxisome proliferator activated receptor- $\gamma$   
  (PPAR $\gamma$ ) 8, 64, 194
- peroxynitrite 120, 125
- p-glycoprotein transporter(s) 250, 251  
  polymorphisms 252
- p-glycoprotein transporter inhibitors 252
- phosphodiesterase (PDE), isoform expression 188
- phosphodiesterase 4 (PDE4)  
  inhibition 189  
  isoenzymes 190
- phosphodiesterase 4 (PDE4) inhibitors  
  selective 188–91  
  side effects 189, 190
- phosphodiesterase (PDE) inhibitors  
  non-selective 185  
  selective 188–91  
  *see also* theophylline

- phosphoinositide 3-kinases (PI3Ks) 223–7  
 classes 223–4  
 reactive oxygen species 226  
 signalling pathway 224
- phosphoinositide 3-kinases (PI3Ks)  
 inhibitors 225  
 selective 225–6  
 small-molecule 226–7
- phospholipase A<sub>2</sub> (PLA<sub>2</sub>) 147
- PI3K $\delta$  224–7
- PI3K $\gamma$  224–7
- placenta, p-glycoprotein expression 251
- planar gamma scintigraphy 268–9
- polyphenols  
 cell signalling modulation 138, 139  
 glucocorticoid signalling 138, 139, 140–1
- positron emission tomography (PET) 268–9
- pranlukast 195
- prednisolone  
 asthma response 93–4, 99  
 severe asthma 98  
 systemic 100
- prednisone, systemic 100
- pressurized metered dose inhaler (pMDI) 262, 266, 269–71
- prolyl hydroxylase 30
- proopiomelanocortin (POMC) 23  
 transactivation 60
- psychiatric side effects 32–3
- psychosis, GC-induced 32–3
- pulmonary targeting 241, 242
- RANKL 26
- RANTES 171
- reactive oxygen species 125–7  
 COPD 65  
 lipid peroxidation products 127  
 PI3Ks 226
- receptor activator of nuclear factor- $\kappa$ B (RANK) 26
- respiratory tract, aerosol deposition 263–6
- rheumatoid arthritis and MIF 146–9  
 COX-2 induction 150  
 regulation by GC 151
- ritonavir, glucocorticoid availability 248
- roflumilast 189, 190, 191
- RU24858 61
- salbutamol 268
- salmeterol 163, 164–5  
 airway remodelling 172  
 dose/timing with inhaled corticosteroids 174  
 GR translocation 175
- inflammatory cells 173–4  
 with inhaled corticosteroid tapering doses 166–7
- SB239063 218, 219
- SCIO-469 220
- sex hormones, bone metabolism 26
- signal transduction and activator of transcription (STAT) family 43, 57  
 GR binding 62, 64
- silent information regulator (SIR2) family 133–4
- single photon emission tomography (SPECT) 268–9
- skin  
 atrophy 29–30  
 GC effects 29–31  
 homeostasis regulation by NF- $\kappa$ B 213  
 SMART (Symbicort® Maintenance And Reliever Therapy) 168–70, 171  
 sodium cromoglycate 268  
 SP600125 222–3  
 spacer devices 271  
 spleen tyrosine kinase (STK) 230  
 splicing, alternative 43, 44, 45–7
- steroid(s) *see* corticosteroid(s); glucocorticoid(s) (GCs)
- steroid-sparing strategies  
 anticholinergics 191–2  
 anti-IgE therapy 196–7  
 ketolides 197–8  
 leukotriene receptor antagonists 193–6  
 leukotriene synthesis inhibitors 193–6  
 long-acting inhaled  $\beta_2$ -agonists 163–78  
 macrolides 197–8  
 mechanisms 175–8  
 modulators of synthesis/action of inflammatory mediators 191  
 theophylline 186–8  
 TNF- $\alpha$  inhibitors 198–200
- stress response genes 58
- superoxide anion 125
- suppressor of cytokine signalling (SOCS) 113
- SYK inhibitors 230
- Symbicort® 168–70, 171
- systemic lupus erythematosus (SLE) and MIF 148  
 regulation by GC 151–2
- T cell(s)  
 activated in corticosteroid-dependent asthma 99  
 CD8<sup>+</sup> 56  
 JNK in maturation/signalling 222
- T cell receptor (TCR) signalling 114
- telithromycin 198

- terbutaline 268, 269  
T-helper (Th) cells  
  circadian rhythm 255  
  type 2 lymphocytes 56  
theophylline  
  cell signalling modulation 138, 139  
  histone deacetylase activation 120, 138  
  LABA combination 188  
  steroid-sparing strategy 186–8  
tiotropium 191, 192  
  LABA additive effect 192  
tissue inflammation 109  
TPCA-1 210, 211, 213, 214  
transcription factors  
  activity modulation 41, 42–3  
  cross-talk with GR 115–16  
translation, alternative 47–9  
tristetrapolin (TTP) 11–12  
tumour necrosis factor (TNF) 150  
tumour necrosis factor  $\alpha$  (TNF- $\alpha$ ),  
  IL-1 $\beta$ -induced 212  
tumour necrosis factor  $\alpha$  (TNF- $\alpha$ )  
  inhibitors 198–200  
tumour necrosis factor  $\alpha$  (TNF- $\alpha$ ) receptors 200  
tyrosine 735 modification 61–2  
tyrosine aminotransferase (TAT) gene 28, 58  
tyrosine kinases, rapid induction 12  
ulcerative colitis, steroid dependency 102  
ultrasonic nebulizers 272  
urine-excretion of drugs 268  
varicella, disseminated infection 28–9  
vascular cell adhesion molecule 1 (VCAM-1) 172  
verapamil 252  
vitamin B6, supraphysiological levels 64  
vitamin D receptors-interacting protein (DRIP)/  
  thyroid-hormone-associated protein (TRAP)  
  complex 85  
VX702 220  
VX745 220  
wortmanin 223, 228  
wound healing, delayed 30  
zafirlukast 195  
zileuton 193, 196  
ZK216348 61–2